Global Dementia Treatment Market, By Types (Alzheimer's Disease Dementia, Vascular Dementia, Dementia With Lewy Bodies (DLB), Parkinson's Disease Dementia, Mixed Dementia, Frontotemporal Dementia, Others), Drug Class (MAO Inhibitors, Glutamate Inhibitors, Cholinesterase Inhibitors, Others), Therapy Type (Cognitive Stimulation Therapy, Cognitive Behavioral Therapy (CBT)), Route of Administration (Oral, Parenteral), By End Users (Hospitals, Homecare ,Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) Industry Trends and Forecast to 2029
Market Analysis and Insights
Dementia is a broad category of mental illnesses that, in the long run, cause a person's ability to think and remember to deteriorate. Despite scientific and medical advances, the causes of dementia have yet to be identified. As a result, the disease is only treated on a symptomatic basis. Nonetheless, movement disorders such as Parkinson's are known to be a trigger for dementia in many cases.
- The Dementia treatment is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the Dementia treatment market will grow at a CAGR of 8.50% during the forecast period of 2022 to 2029.
Dementia Treatment Market Dynamics
Drivers
- Growing ageing population as well as rise in healthcare infrastructure
The high prevalence of dementia is driving the growth of the dementia treatment market. Treatment advancements and the development of novel therapies for dementia will also contribute to the growth of the dementia treatment market. Furthermore, the vulnerable ageing population can be viewed as a positive measure for the growth of this market. Furthermore, the growth of this market can be attributed to government incentives and benefits through special designation. Increasing investment for healthcare infrastructure
Accelerated technological advancements in drug discovery techniques and high government investment in drug development are factors that present new pathways in the industry.
Opportunities
- Rise in the investment for R&D by public and private organizations
Furthermore, rising R&D activities in disease-modifying drugs, as well as an increase in investment by key players in clinical studies of advanced treatment options, are expected to propel the dementia associated with Alzheimer's disease market during the forecast period.
Restraints/Challenges
However, strict government regulations governing product approval and the high costs associated with Research and development activities are expected to impede market growth.
This Dementia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Dementia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
According to Alzheimer's Disease International, there will be more than 50 million people with dementia worldwide by 2020. This figure is expected to more than double every 20 years, reaching 82 million in 2030 and 152 million in 2050.
According to the National Clinical Trials (NCT) Registry, Eli Lilly and Company is conducting a phase III clinical trial in participants with early Alzheimer's disease to evaluate the safety and efficacy of donanemab. The trial began in June 2020 and is scheduled to end in December 2023.
Dementia treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Covid-19 Impact on Dementia Treatment Market
The COVID-19 pandemic outbreak is expected to have a significant impact on the Dementia drugs market. Dementia patients are at a high risk of contracting COVID-19 infection because their cognitive symptoms make it difficult to follow the safety guidelines proposed to control viral spread. Furthermore, older populations with dementia are more likely to have more severe disease consequences than younger populations without dementia. However, the COVID-19 pandemic is expected to harm new product launches, which are expected to be the most important factor in market growth.
Recent Development
- In January 2021, LSP, the leading European life sciences investor, and Professor Philip Scheltens, a world-renowned dementia scientist, will launch the LSP Dementia Fund, a fund dedicated to fighting neurodegenerative diseases, in Amsterdam.
- Alzheimer's Disease International, in collaboration with the Global Coalition on Aging (GCOA) and the Lien Foundation, will launch the third Dementia Innovation Readiness Index in 30 global cities around the world in October 2020.
Global Dementia Treatment Market Scope
The Dementia treatment market is segmented on the basis of types, drug class, therapy type, route of administration, end-users and distribution channel.. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Alzheimer's Disease Dementia
- Vascular Dementia
- Dementia With Lewy Bodies (Dlb)
- Parkinson's Disease Dementia
- Mixed Dementia
- Frontotemporal Dementia
On the basis of types, the dementia treatment market is segmented into alzheimer's disease dementia, vascular dementia, dementia with lewy bodies (DLB), parkinson's disease dementia, mixed dementia, frontotemporal dementia, others.
Drug Class
- MAO Inhibitors
- Glutamate Inhibitors
- Cholinesterase Inhibitors
- Others
The drug class segment for dementia treatment market includes MAO inhibitors, glutamate inhibitors, cholinesterase inhibitors and others.
Therapy type
- Cognitive Stimulation Therapy
- Cognitive Behavioral Therapy (CBT)
On the basis of therapy type, dementia treatment market is segmented into cognitive stimulation therapy, and cognitive behavioral therapy (CBT)).
Route of Administration
- Oral
- Parenteral
On the basis of route of administration, the Dementia treatment market is segmented into oral and parenteral
End Use
- Clinic
- Hospital
- Others
On the basis of end-users, the Dementia treatment market is segmented into clinic, hospital and others.
Distribution Channel
- Hospital Pharmacy
- Special clinics
- Others
The Dementia treatment market is also segmented on the basis of distribution channel into hospital pharmacy, special clinics and others
Pipeline Analysis
The pipeline analysis of anticonvulsant drugs includes various pipeline therapies such as LP352, OPC-214870, Ganaxolone, CT-010, Vatiquinone E-2730, XEN496, and NBI 827104. Otsuka Pharmaceutical Co. Ltd, Marinus Pharmaceuticals, Cerebral Therapeutics LLC, PTC Therapeutics, Xenon Pharmaceuticals, Longboard Pharmaceuticals, Eisai, Neurocrine Biosciences and others are the involved in the development of potential drugs for the improvement of treatment of seizures.
Dementia Treatment Market Regional Analysis/Insights
The Dementia treatment market is analysed and market size insights and trends are provided by country, types, drug class, therapy type, route of administration, end-users and distribution channel. as referenced above.
The countries covered in the Dementia treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America was the leading revenue contributor to the dementia treatment market due to the increasing incidence of dementia and the presence of key players in the same geography, whereas Asia-Pacific is expected to maintain significant growth due to increased dementia awareness programmes and the availability of effective drugs in this region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Dementia Treatment Market Share Analysis
The Dementia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Dementia treatment market.
Some of the major players operating in the Dementia treatment market are Eisai Co., Ltd., Novartis AG, Cipla Inc, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd, Mylan N.V., Dr. Reddy’s Laboratories Ltd, Zydus Cadila, LUPIN, Torrent Pharmaceuticals Ltd, Jubilant Life Sciences Ltd, Alembic Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc, Hikma Pharmaceuticals PLC, Allergan, Lannett and others.
SKU-